Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) · 2020
DOI: 10.32734/jetromi.v2i3.4293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI), 2020. Verfasst von Rasyidah Hasan Harahap und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Restless Legs Syndrome (RLS) is one of the most common sleep disturbance problems in dialysis patients. In this study, we would like to explore some of bone and mineral marker disorder especially fibroblast growth factor-23 (FGF-23)and its correlation with RLS in regular hemodialysis patients.
Methods
This is a cross sectional study design involving 71 respondents with chronic kidney disease that already had regular hemodialysis at Haji Adam Malik Hospital Medan. Status of RLS in this patients were being evaluated according to the International Restless Leg Syndrome Study Group (IRLSG) by interviewing and laboratory examination of FGF-23, hemoglobin (Hb), serum iron (SI), total iron binding capacity (TIBC), transferrin saturation (TSAT), serum ferritin, calcium (Ca) and phosphate (P) level.
Results
Of all study subjects, 26 respondents (34.6%) diagnosed with RLS. Bivariate analysis result showed that there is a relationship between FGF-23, hemoglobin, phosphate, and transferrin saturation level with RLS. Logistic regression analysis used to see the most dominant factor of all.
Conclusion
This study conclude that increase in FGF-23 levels can increase the risk of RLS. However, FGF-23 is not the most dominant risk factor for RLS in regular hemodialysis patients.
Zitieren
APA
Harahap, R. H., Muzasti, R. A., & Nasution, A. T. (2020). Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome. Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI). https://doi.org/10.32734/jetromi.v2i3.4293
Vancouver
Harahap RH, Muzasti RA, Nasution AT. Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome. Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI). 2020. doi:10.32734/jetromi.v2i3.4293
BibTeX
@article{Harahap2020,
author = {Harahap, Rasyidah Hasan and Muzasti, Riri Andri and Nasution, Alwi Thamrin},
title = {Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome},
journal = {Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI)},
year = {2020},
doi = {10.32734/jetromi.v2i3.4293}
}
EUVIMED